Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study
Yoshinobu Kanda, Katsuto Takenaka, Tatsu Tanabe, Kazuya Omoto, Kei Kamimura, Kentaro Kudou, Masato Kaneko · 2026
Read Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study by Yoshinobu Kanda, Katsuto Takenaka, Tatsu Tanabe, Kazuya Omoto, Kei Kamimura, Kentaro Kudou, Masato Kaneko (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13529860.txt.
Description
Yoshinobu Kanda and six colleagues report a phase three trial of maribavir for cytomegalovirus in Japanese transplant patients in a 2026 study. The virus threatens people whose immunity is suppressed after grafts. Sixty-one patients enrolled at twenty-two sites. Forty-one received the oral drug, twice daily for eight weeks. Most were stem cell transplant recipients.
By week eight about sixty-eight percent had cleared the virus from blood, confirmed by repeat tests. About eighty-eight percent reported some side effect. Nausea led at about twenty-four percent, then anemia, fever, and headache. Two deaths occurred and were judged unrelated to the drug. The authors call the balance of benefit and tolerability acceptable. The group included patients whose infections resisted standard drugs. Maribavir thus fills a real gap in post-transplant care.
Catalog record
| CREATOR | Yoshinobu Kanda, Katsuto Takenaka, Tatsu Tanabe, Kazuya Omoto, Kei Kamimura, Kentaro Kudou, Masato Kaneko |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53984 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |